Diabetic ketoacidosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2] Hibatullah Abdul Aleem, M.B.B.S[3]

Diabetic ketoacidosis (DKA) is a medical emergency. The mainstay of therapy for diabetic ketoacidosis is medical therapy comprising intravenous fluids, intravenous insulin, and potassium replacement, with selective use of bicarbonate and phosphate. The four pillars of management are restoration of circulating volume and tissue perfusion, insulin to shut off ketogenesis and correct hyperglycemia, correction of electrolyte and acid-base derangements, and treatment of the precipitating cause, with close monitoring to prevent iatrogenic complications (hypoglycemia, hypokalemia, cerebral edema). The intravenous insulin infusion is continued until ketoacidosis resolves, not merely until glucose normalizes. Guideline-based fluid composition and bicarbonate thresholds differ between the American Diabetes Association (ADA) and the Joint British Diabetes Societies (JBDS), and both values are preserved here rather than reconciled.

The acute management of diabetic ketoacidosis rests on prompt fluid resuscitation, a fixed-rate or weight-based insulin infusion, potassium replacement guided by serial monitoring, and treatment of the precipitating illness.^[1][2]

• In adults without shock, give 1 L of 0.9% saline over the first hour, then 250-500 mL/h titrated to volume status; deficits are replaced over 24-48 hours.^[2]
• Saline-based fluids remain guideline-preferred over balanced crystalloids, as no definitive benefit for balanced crystalloids has been shown.^[2]
• Fluid-composition guidance differs by society: JBDS recommends 0.9% saline throughout, whereas ADA recommends 0.45% saline when corrected sodium is normal or high and 0.9% saline when corrected sodium is low.^[2]
• Add dextrose (e.g., D5) to fluids once blood glucose reaches 250 mg/dL to permit continued insulin while avoiding hypoglycemia.^[2]

• Start insulin 1-2 hours after beginning fluid resuscitation, not simultaneously.^[2]
• For moderate to severe DKA, use a continuous intravenous regular insulin infusion at 0.1 unit/kg/h; a bolus is optional and may be omitted.^[2][1]
• If a nurse-driven variable-rate protocol is used, the ADA specifies the rate should be no less than 1 unit/h to allow acidosis to resolve.^[1]
• Target a glucose fall of approximately 50 mg/dL/h and a bicarbonate rise of approximately 3 mEq/L/h; if these targets are not met, increase the infusion by 1 unit/h.^[2]
• In children, start at 0.05-0.1 unit/kg/h (lower rates for younger children and non-severe DKA); if acidosis is not resolving by 6-8 h and other causes are excluded, increase to 0.1 unit/kg/h.^[2]
• Once glucose reaches 250 mg/dL, decrease the infusion to 0.05 unit/kg/h and add dextrose.^[2]
• The intravenous infusion is continued until ketoacidosis resolves, not merely until glucose normalizes.^[2]

• Mild, uncomplicated DKA can be managed with subcutaneous rapid-acting analogs (lispro or aspart) every 1-2 h, given in the emergency department or step-down units rather than the ICU.^[1]
• A typical regimen is 0.3 unit/kg subcutaneous bolus, then 0.1 unit/kg hourly (or 0.2 unit/kg every 2 h).^[2]
• Outcomes are comparable to intravenous regular insulin for mild to moderate DKA when combined with aggressive fluids, and the approach may be safer and more cost-effective.^[1]
• Implementation studies show reduced emergency department length of stay and lower ICU utilization without excess hypoglycemia.^[3][4][5]
• Adequate fluids, frequent point-of-care glucose monitoring, treatment of infection, and follow-up remain essential.^[1]

• Adding low-dose long-acting basal insulin (glargine or degludec, approximately 0.15-0.3 unit/kg) early alongside the intravenous infusion accelerates DKA resolution and reduces total intravenous insulin requirement.^[6][1]
• ]The absence of increased hypoglycemia or hypokalemia applies chiefly to adults; in pediatrics, one review of 149 children found increased hypokalemia, so the approach should be used cautiously in that population.^[2]

• Total-body potassium is depleted despite normal or high serum levels. Confirm urine output before replacement.^[2]
• If potassium is below 3.3 mEq/L, hold insulin and give 20–30 mEq/h until potassium exceeds 3.3 mEq/L, to avoid precipitating life-threatening hypokalemia and arrhythmia.^[2][7]
• If potassium is 3.3-5.2 mEq/L, add 20-30 mEq to each liter of intravenous fluid to maintain potassium at 4-5 mEq/L.^[2][7]
• If potassium exceeds 5.2 mEq/L, give no potassium and recheck every 2 hours.^[2][7]

• Bicarbonate, phosphate, and magnesium are not routinely recommended.^[2]
• ADA 2026 found bicarbonate made no difference in resolution or time to discharge and is generally not recommended, without endorsing a pH cutoff.^[1]
• Where bicarbonate is considered, thresholds differ across sources and both are preserved: the historical consensus threshold is pH <6.9 in adults, children should not receive bicarbonate unless pH <6.9, and one adult teaching approach individualizes use at pH <7.2 with bicarbonate <12 mmol/L if hemodynamically unstable.^[8]
• If bicarbonate is given (e.g., pH 6.9-7.0), a representative regimen is 50 mmol sodium bicarbonate diluted in 200 mL with 10 mEq KCl over 1 h, repeated every 2 h until pH exceeds 7.0, with potassium monitoring.^[7]
• Phosphate replacement is reserved for severe hypophosphatemia with cardiac dysfunction, respiratory compromise, or anemia; over-replacement causes hypocalcemia.^[2]

• Point-of-care glucose and β-hydroxybutyrate hourly; electrolytes and pH every 2-4 h.^[2]

• DKA is resolved when clinical status improves and: blood glucose <200 mg/dL, venous pH >7.3, bicarbonate ≥18 mEq/L, anion gap normalized, and β-hydroxybutyrate normalized.^[2]
• β-hydroxybutyrate and anion-gap closure are preferred over bicarbonate for judging resolution, since large-volume 0.9% saline induces hyperchloremic acidosis that suppresses bicarbonate independently of ketosis.^[2]

• When transitioning off the intravenous infusion, give subcutaneous basal insulin 2-4 h before stopping the drip to prevent rebound hyperglycemia and recurrent DKA; overlap rapid-acting subcutaneous insulin with the infusion by 30-60 minutes (pumps by 60 minutes).^[1]
• The total daily subcutaneous dose can be based on the prior home regimen, a weight-based estimate (0.5-0.8 unit/kg/day, split approximately 50/50 basal/prandial), or extrapolated from the stable infusion rate over the prior 6-8 h.^[1][2]

• Regimens require modification in pregnancy, heart failure, acute coronary syndrome, and end-stage renal disease; detailed management is addressed in the dedicated special-populations content.^[2]

Abbreviations: DKA, diabetic ketoacidosis; K, potassium; SC, subcutaneous; β-hydroxybutyrate, beta-hydroxybutyrate.

^[9]

The following oral glucose-lowering agents are contraindicated or should be held in the setting of diabetic ketoacidosis; note these concern chronic outpatient diabetes pharmacotherapy rather than acute inpatient management.

Diabetic ketoacidosis is considered an absolute contraindication to the use of the following medications:

• Glipizide
• Glyburide
• Glyburide and Metformin
• Linagliptin and Metformin hydrochloride
• Repaglinide
• Saxagliptin hydrochloride and Metformin hydrochloride

Template:WH Template:WS